Last reviewed · How we verify
standard adjuvant chemotherapy plus moxifloxacin
Moxifloxacin is a broad-spectrum antibiotic that inhibits bacterial DNA replication by binding to the bacterial DNA gyrase and topoisomerase IV.
Moxifloxacin is a broad-spectrum antibiotic that inhibits bacterial DNA replication by binding to the bacterial DNA gyrase and topoisomerase IV. Used for Community-acquired pneumonia, Skin and skin structure infections, Complicated urinary tract infections.
At a glance
| Generic name | standard adjuvant chemotherapy plus moxifloxacin |
|---|---|
| Also known as | Standard adjuvant chemotherapy (Docetaxel combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by docetaxel) plus antibiotic (moxifloxacin) |
| Sponsor | Sun Yat-sen University |
| Drug class | fluoroquinolone antibiotic |
| Target | DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
This action results in the inhibition of bacterial DNA replication and transcription, ultimately leading to bacterial cell death. Moxifloxacin is a fluoroquinolone antibiotic, which is a class of drugs that target bacterial DNA enzymes. By inhibiting these enzymes, moxifloxacin is able to effectively treat a wide range of bacterial infections.
Approved indications
- Community-acquired pneumonia
- Skin and skin structure infections
- Complicated urinary tract infections
- Acute bacterial sinusitis
Common side effects
- Nausea
- Diarrhea
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: